Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chi-Fu Jeffrey Yang, MD
Massachusetts General Hospital
Study Chair - Jacob Sands, MD
Dana-Farber Cancer Institute
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Illinois Chicago
Chicago, Illinois, United States
Recruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Feb 2026
- Primary completion
- 28 Feb 2029
- Completion
- 28 Feb 2031
- Last update posted
- 26 Jun 2026
- Registered enrollment
- 65
- Registry id
- NCT07149363
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.